A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
An international team of researchers have successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice.
A recent study, utilizing new research methods, has demonstrated how Zika virus may suppress gene transcription reducing immune response in human macrophage cells.
Since Zika broke into the news in 2016, new research has been uncovering more information about this virus – we spoke to Dustin Farr at the recent ASM Microbe meeting where he was presenting a poster on Zika infection in corneal cells.
Is Zika congenital syndrome, which affected thousands of babies born in Brazil during epidemics, associated with an increased host genetic susceptibility? And could Zika be a strong oncolytic agent against aggressive brain tumors? Find out in this opinion piece.
At ASM Microbe GeoVax have spoken on the development of single-dose vaccines for emerging diseases using their MVA ‘Plug and Play’ platform technology.
For the first time, Brazilian researchers have demonstrated the efficacy of the Zika virus in treating advanced-stage human CNS tumors in vivo.
With Zika research primarily focusing on in utero infections, new work has used a monkey model to study infants infected in their first year of life, uncovering adverse neurological consequences.
Roche has this week announced the launch of a new fully-automated IgG Zika assay, Elecsys®, which it hopes will help address the urgent need for accurate Zika diagnosis.
A recent study has presented an accurate estimation of pregnancy outcomes associated with Zika infection in French territories in the Americas.